Most of us are aware of the concept of drug side effects, which can be either negative or positive. The goal of any drug ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023. [Photo: Brendan ...

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

It's the same story with stocks. We saw that happen with Eli Lilly (NYSE: LLY) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big ...

In this article, we are going to take a look at where Eli ... Lilly is developing next-generation drugs, including retatrutide, which drives approximately 25% weight loss, and orforglipron, a ...

It's shaping up to be a tough period for Eli Lilly and Company (NYSE:LLY), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market ...

Some investors could be tempted to sell. I think that's a temptation to avoid. Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update are overblown It's not ...